Therapeutic Antibody & Biosimilar ELISA Kits
Therapeutic Antibody & Biosimilar ELISA Kits
Quantitative and Qualitative Free Drug and ADA ELISA for Biologics & Biosimilars
Why choose ELISA for Drug Monitoring?
- Validated for Cancer, Autoimmune diseases, Osteoporosis, Macular Degeneration research & more
- Qualitative, quantitative & free/total kits for full screening of antibodies.
- Sensitivity and limit of detection in the ng/mL range.
- Validated in serum and/or plasma from human, mouse & NHP samples
Our TDM & ADA ELISA Range
Therapeutic mAb ELISA
Screening & quantification
Biosimilar ELISA
Desgined for QC and biosimilarity assessment
ADA ELISA
For detection of ADA againts therapeutic mAbs
Custom ELISA
Development of custom assay upon request
Popular Targets
Testimonials & Partners
"Assay Genie provided a critical ELISA kit that is very difficult to find on the market. Not only did this kit work dependably well, but it also provided me with the measurement sensitivity that I needed to evaluate my samples."
- Erika on Trustpilot
Citations
Product | Citation |
|---|---|
Chemical Communications Sensi et al. | |
Cancer Chemotherapy and Pharmacology Gandhi et al. | |
Delivery in 7-10 business days
24 hours on LiveChat & PhD Level support
Competitive ELISA prices
Ensuring reproducible results
cGMP & ISO Certification
Quality is at the core of everything we do.
Manufactured in state-of-the-art facilities, our products meet the highest standards, including current Good Manufacturing Practicies) cGMP, ISO 9001:2015, and ISO 13485:2016 certifications. These ensure consistent quality, customer-focused innovation, and reliable performance in every batch.
ELISA Manufacture Pipeline
Assay Genie ELISA Kits are developed through a rigorous pipeline, from gene synthesis and protein/peptide production to antibody generation and pairing. Each assay undergoes validation to ensure accuracy before ELISA kit production, delivering reliable results for researchers worldwide.
Detection Principle & Protocol
An ELISA protocol involves coating a microplate with a specific capture antibody, adding the sample containing the target analyte, and incubating to allow binding. After washing to remove unbound substances, a detection antibody (linked to an enzyme) is added, followed by a substrate solution that produces a measurable color change. The optical density (OD) is read using a spectrophotometer, with absorbance values correlating to analyte concentration.
What are Therapeutic Antibodies & ADAs?
- Therapeutic mAbs | Designed to bind specific targets and modulate the immune responses or block disease-related pathways.
- Biosimilars | Highly similar versions of approved therapeutic mAbs, while offering a more cost-effective alternative.
- Anti-Drug Antibodies (ADAs) | Immune-generated antibodies that can bind or neutralize therapeutic mAbs, reducing effectiveness.
Why is drug monitoring important ?
- Optimized Dosing | Ensures therapeutic drug concentrations remain within the optimal range for maximum efficacy.
- Reduced Immunogenicity | Prevents overdosing-related side effects and identifies ADA formation that may reduce drug effectiveness.
- Personalized Treatment | Enables dose adjustments based on individual patient responses, improving long-term outcomes
Applications & Data
Therapeutic mAb & Biosimilar ELISA
- Quality Control | ELISA can be used for QC during the development and manufacturing of antibodies
- Biosimilarity assessment | Test similarity between biosimilar and reference product
- PK studies | Assess how mAbs move through the body and help to determine optimal dosing.
- Clinical Development | Monitor the presence of therapeutic & biosimilar mAb in patient samples
Standard Curve Adalimumab ELISA Kit (HUMB00009).
Data from Anti-Adalimumab Free Drug/ADA Dual ELISA (HUMB00012)
Anti-Drug Antibody (ADA) ELISA
- Immunogenicity Assessment | High levels of ADAs may neutralize the therapeutic effects of the drug, rendering it less effective.
- Response Variability | Identify differences in patients response by measuring ADA levels
- Biosimilarity Evaluation | Helps to assess the immunogenicity profile of biosimilars to reference product
- Free vs. Total ADA | Acid dissociation technology breaks antibody complex making ADA detectable
Meet Some of the Genie Team!
At Assay Genie, we're here to help every step of the way. Whether you need guidance choosing the right product, updates on your order, or expert support after your purchase, we've got you covered.
Colm, CEO
Sean, CSO
Shane, Sales
Beatriz, Logistics
José, Sales
Miren, Sales
Natalia, Tech Support
David, Sales
Joe, Sales
Marina, Tech Support
Chris, Sales
Shivaun, Logistics
FAQs - Therapeutic mAb & Biosimilar ELISA Kit
The kit is shipped at ambient temperature (10-30°C) and should be stored at 2-8°C for long term storage. Keep away from heat or direct sunlight.
Possible Cause | Possible Solution |
Reagents not at room temperature | All reagents should at room temperature from the start of the assay. Room temperature should be reached following 15–20 minutes on the bench. |
Incubation time too short | Follow manufacturer guidelines in the technical manuals |
Incorrect wavelength | Manufactured kits have optimized protocols. Make sure to use recommended wavelength. Ensure plate reader is set accurately for type of substrate being used |
Target present below detection limits of assay | Decrease dilution factor or concentrate samples |
Reagents are poorly mixed, the standard has degraded or pipetting errors.
For more troubleshooting suggestions vist our 101 ELISA Troubleshooting Tips!
Research related ELISA Kits
Current therapeutic antibodies prevent angiogenesis, immune cell evasion and apoptosis inhibition and are used in lung cancer, colon cancer, glioblastomas, solid tumours, breast cancer, colorectal cancer and multiple myeloma.
| Anti-Ramucirumab (Cyramza®) ADA | |
|---|---|
| Product Code | HUMB00023 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00028 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00029 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Trastuzumab (Herceptin®, Herclon®) ADA | |
|---|---|
| Product Code | HUMB00031 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Trastuzumab (Herceptin®, Herclon®) ADA | |
|---|---|
| Product Code | HUMB00032 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Cetuximab (Erbitux®) ADA | |
|---|---|
| Product Code | HUMB00034 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Cetuximab (Erbitux®) ADA | |
|---|---|
| Product Code | HUMB00035 |
| ELISA Type | Antibody screening - Quantitative |
| Daratumumab (Darzalex®) ADA | |
|---|---|
| Product Code | HUMB00063 |
| ELISA Type | Antibody screening - Qualitative |
Increasing knowledge of how tumours undergo immune evasion has led to the discovery of drugs called checkpoint inhibitors. These immunotherapies can prevent this override of the immune system, and allow the cancer to be detected and destroyed. These biologics are currently used to treat Merkel Cell Carcinoma (MCC), Melanoma, lung cancer, renal cell carcinoma and head and neck cancer.
| Anti-Avelumab (Bavencio®) ADA | |
|---|---|
| Product Code | HUMB00043 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Nivolumab (Opdivo®) ADA | |
|---|---|
| Product Code | HUMB00045 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Pembrolizumab (Keytruda®) ADA | |
|---|---|
| Product Code | HUMB00047 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Ipilimumab (Yervoy®) ADA | |
|---|---|
| Product Code | HUMB00049 |
| ELISA Type | Antibody screening - Qualitative |
| Atezolizumab (Tecentriq®) ADA | |
|---|---|
| Product Code | HUMB00061 |
| ELISA Type | Antibody screening - Qualitative |
While providing us defence against pathogens, the immune response can also turn inwards and trigger autoimmune disorders. Knowledge of the biochemical pathways involved in inflammation has allowed researchers to target specific agents with therapeutic antibodies/biologics to decrease disease burden, such as arthritis, inflammatory bowel disease, psoriasis, muckle wells disease and many more.
| Anti-Vedolizumab (Entyvio®) ADA Qualitative ELISA Kit | |
|---|---|
| Product Code | HUMB00019 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Ustekinumab (Stelara®) ADA | |
|---|---|
| Product Code | HUMB00021 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Tocilizumab (Actemra®) | |
|---|---|
| Product Code | HUMB00051 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Natalizumab (Tysabri®) ADA | |
|---|---|
| Product Code | HUMB00053 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Canakinumab (Ilaris®) ADA | |
|---|---|
| Product Code | HUMB00057 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Abatacept (Orencia®) ADA | |
|---|---|
| Product Code | HUMB00069 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Secukinumab (Cosentyx® , Verxant®) ADA | |
|---|---|
| Product Code | HUMB00067 |
| ELISA Type | Antibody screening - Qualitative |
| Palivizumab (Synagis®) Qualitative ELISA | |
|---|---|
| Product Code | HUMB00071 |
| ELISA Type | Antibody screening |
Dysregulation in TNFα signalling is a common occurrence in inflammatory disorders. Thus, a range of therapeutic antibodies have been developed to treat a number of pathologies such as; rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Using TDM for these antibodies during treatment is of great benefit in monitoring patient response, optimising dosage and preventing immunogenicity.
| Anti-Infliximab (Remicade®) ADA | |
|---|---|
| Product Code | HUMB00002 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Infliximab (Remicade®) ADA | |
|---|---|
| Product Code | HUMB00003 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Infliximab (Remicade®) Free Drug/ADA Dual ELISA | |
|---|---|
| Product Code | HUMB00004 |
| ELISA Type | Antibody screening - Free/Total semiquantitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00006 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00007 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00008 |
| ELISA Type | Antibody screening - Total semiquantitative |
| Anti-Adalimumab (Humira®) ADA | |
|---|---|
| Product Code | HUMB00010 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Adalimumab (Humira®) ADA | |
|---|---|
| Product Code | HUMB00011 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA | |
|---|---|
| Product Code | HUMB00012 |
| ELISA Type | Antibody screening - Free/Total semiquantitative |
| Anti-Etanercept (Enbrel®) ADA | |
|---|---|
| Product Code | HUMB00014 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Golimumab (Simponi®) ADA | |
|---|---|
| Product Code | HUMB00016 |
| ELISA Type | Antibody screening - Qualitative |
Macular degeneration is a debilitating illness of the eye that ultimately releases in loss of central vision. Most treatments involve biologics that target VEGF or its receptors to prevent damaging angiogenesis.
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
Incidences of allergy and allergic asthma are on the rise worldwide. Treatments for asthma focus on treating the secondary symptoms. Biologics have been created to bind to free IgE in the treatment of asthmatics who are unresponsive to corticosteroids.
| Anti-Omalizumab (Xolair®) ADA | |
|---|---|
| Product Code | HUMB00040 |
| ELISA Type | Antibody screening - Qualitative |
Neutropenia refers to an abnormally low concentration of neutrophils in the blood, and can result in a range of harmful side effects that is commonly seen in patients receiving chemotherapy and HIV. It can be treated with exogenous G-CSF.
Biologics have been developed to combat obesity that present with hyperlypidemia to allow LDL to be removed from the blood.
| Evolocumab (Repatha® ) ADA | |
|---|---|
| Product Code | HUMB00065 |
| ELISA Type | Antibody screening - Qualitative |
With age and hormone changes, alterations occur in bone homeostasis that lead to degeneration of bone cells. By targeting RANK-L, it is possible to prevent the growth of osteoclasts that breakdown bone.
| Anti-Denosumab (Prolia®) ADA | |
|---|---|
| Product Code | HUMB00037 |
| ELISA Type | Antibody screening - Qualitative |
Related Resources - Blogs & Podcast Episodes
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the mechanism of action for Siltuximab?Siltuximab binds to IL-6, preventing it from interacting with its receptor and mitigating downstream pro-inflammatory signaling.What [...]
Additional Resources
